Global Frasier Syndrome Market, By Type (Fraser syndrome 1 (FRASRS1), Fraser syndrome 2 (FRASRS2), Fraser syndrome 3 (FRASRS3)), Diagnosis (Genetic Testing, Imaging Tests, Kidney Biopsy, Others), Treatment (Surgery, Kidney Transplantation, Medication, Others), Age of Onset (Childhood, Adolescent, Adult), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Frasier syndrome is a sex development abnormality that affects a small number of people. A mutation in Wilms' tumor suppressor gene (WT-1) on chromosome 11p23 causes it. This gene codes for a transcription factor involved in kidney and gonad development. In 46, XY patients, the syndrome is characterized by female external genitalia, streak gonads, and an increased risk of gonadal cancer, primarily gonadoblastoma. The nephrotic syndrome (NS) is a kind of nephropathy caused by focal segmental glomerular sclerosis (FSGS). NS appears in childhood and is resistant to steroid and immunosuppressive therapy.
Data Bridge Market Research analyses that the Frasier syndrome market was valued at USD 298 million in 2021 and is expected to reach USD 383.40 million by 2029, registering a CAGR of 3.20% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Fraser syndrome 1 (FRASRS1), Fraser syndrome 2 (FRASRS2), Fraser syndrome 3 (FRASRS3)), Diagnosis (Genetic Testing, Imaging Tests, Kidney Biopsy, Others), Treatment (Surgery, Kidney Transplantation, Medication, Others), Age of Onset (Childhood, Adolescent, Adult), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Allergan (Ireland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Hikma Pharmaceuticals PLC (U.K.), Bristol-Myers Squibb Company (U.S.), Bayer AG (Germany), Boehringer Ingelheim International GmbH. (Germany), Dr. Reddy’s Laboratories Ltd. (India), Gilead Sciences, Inc. (U.S.), Amgen Inc. (U.S.), Eli Lilly and Company (U.S.), AbbVie Inc. (U.S.), Lupin (India), Allergan (Ireland)
|
|
Market Opportunities
|
|
Market Definition
Frasier syndrome is a rare hereditary syndromic glomerular condition marked by progressive glomerular nephropathy and 46, XY complete gonadal dysgenesis, as well as a significant risk of gonadoblastoma. Fraser syndrome has no known cure at this time. Surgical correction of some of the abnormalities associated with FS may be required, depending on the severity of the anomalies. Symptomatic and supportive treatment is the only other option. Without therapy, the prognosis is determined by the severity of the patient's individual defects, particularly respiratory tract malformations and anal imperforations.
Frasier Syndrome Market Dynamics
Drivers
- Rising incidences of Frasier syndrome
The surging incidences of Frasier syndrome is a major factor driving the market's growth rate during the forecast period of 2022-2029. The kidney condition that occurs in early childhood is known as Frasier syndrome. Affects persons have focal segmental glomerulosclerosis, a disorder in which scar tissue grows in some glomeruli, which are small blood arteries in the kidneys that filter waste from the blood. Frasier syndrome is a disorder that often leads to renal failure by adolescence in persons who have it.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of Frasier syndrome market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, rising government initiatives to spread awareness and sedentary lifestyle of people will result in the expansion of Frasier syndrome market. Along with this, favourable reimbursement policies and surging pediatric population will enhance the growth rate of the market.
Opportunities
- Increase in the number of research and development activities
The market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the Frasier syndrome market growth.
Moreover, the market's growth is fueled by rising technological advancement in diagnostic methods and emerging new markets. These factors will provide beneficial opportunities for the Frasier syndrome market growth.
Restraints/Challenges
On the other hand, high cost associated with the available treatment as well as diagnosis will obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the Frasier syndrome market. Additionally, lack of cure as well as awareness about genetic diseases and unfavourable healthcare policies will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This Frasier syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Frasier syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Fraser syndrome affects both men and women equally. This condition has a neonatal/antenatal onset, which means that an affected individual develops it before birth. FS is more common in gypsy (Roma ethnicity) people in southern and Eastern Europe. FS affects 0.43 out of 10,000 new-borns (1 out of 200,000) and 11.06 out of 10,000 babies who die before birth (stillbirths).
Frasier syndrome market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Global Frasier Syndrome Market Scope
The Frasier syndrome market is segmented on the basis of type, diagnosis, treatment, age of onset, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Fraser syndrome 1 (FRASRS1)
- Fraser syndrome 2 (FRASRS2)
- Fraser syndrome 3 (FRASRS3)
Age of Onset
- Childhood
- Adolescent
- Adult
Route of Administration
- Oral
- Parenteral
- Others
Diagnosis
- Genetic Testing
- Imaging Tests
- Ultrasound
- Others
- Kidney Biopsy
- Others
Treatment
- Surgery
- Kidney Transplantation
- Medication
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Frasier Syndrome Market Regional Analysis/Insights
The Frasier syndrome market is analyzed and market size insights and trends are provided by country, type, diagnosis, treatment, age of onset, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Frasier syndrome market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the Frasier syndrome market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing prevalence of Frasier syndrome and rising healthcare expenditure will further propel the market’s growth rate in this region. Additionally, growing presence of major key players will further propel the market’s growth rate in this region.
Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to development of healthcare infrastructure in this region. Also, rising government initiatives will further propel the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Frasier Syndrome Market Share Analysis
The Frasier syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Frasier syndrome market.
Some of the major players operating in the Frasier syndrome market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Merck & Co., Inc. (U.S.)
- Allergan (Ireland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Hikma Pharmaceuticals PLC (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Bayer AG (Germany)
- Boehringer Ingelheim International GmbH. (Germany)
- Dr. Reddy’s Laboratories Ltd. (India)
- Gilead Sciences, Inc. (U.S.)
- Amgen Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- AbbVie Inc. (U.S.)
- Lupin (India)
- Allergan (Ireland)
SKU-